Drug intelligence / Profile preview

IBIS-SARS-CoV

Development stage: Preclinical
Lead developer: Canthevac
Modality: Vaccines & Immunotherapeutics

Overview

IBIS-SARS-CoV is a preventive vaccine candidate currently in preclinical development by Canthevac. It is designed to elicit a protective immune response against SARS-CoV-like viruses, targeting indications such as Severe Acute Respiratory Syndrome (SARS) and COVID-19. The vaccine is part of Canthevac's IBIS platform, which aims to address various viral respiratory infections by leveraging a proprietary vaccine technology to generate broad immunity against related viral strains.

Beyond the preview

Go deeper on IBIS-SARS-CoV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IBIS-SARS-CoV.

Explore the full profile